The major shortcoming of the PSA test is its less-than-perfect sensitivity and specificity rates, despite the fact that these rates are among the highest of cancer screening tests currently in use. Approximately 25% to 33% of patients with prostate cancer have serum PSA concentrations in the normal range at the time of diagnosis, made on PHI has been shown to be superior to total PSA and percent free PSA in detecting prostate cancer including aggressive prostate cancer , , , . Thus, following a meta-analysis of eight studies (n=2919 patients), the pooled sensitivity of PHI for the detection of prostate cancer was 90% while the pooled specificity was 31.6% [ 83 ]. Although DRE has high specificity for prostate cancer, it has a low sensitivity profile and is not considered an effective detection tool on its own. 108 In contemporary series, 109 PSA testing with a threshold of 4.0 ng/mL has a sensitivity of only about 20%. Although the sensitivity of PSA testing could be improved by lowering the threshold Prostate cancer screening with the prostate-specific antigen (PSA) test or digital rectal exams has not been shown to reduce prostate cancer deaths. Get detailed information about prostate cancer screening, including potential benefits and harms, in this summary for clinicians. the sensitivity of DRE for prostate cancer was 16.7%. The The Prostate Cancer Prevention Trial (PCPT) 18 uniquely showed that, at a PSA threshold of 3 ng/ml, the sensitivity of PSA for Gleason score ≥3 + 4 was 58%; the threshold would have to be Screening for prostate cancer is primarily performed using the DRE and PSA test, yet the specificity and sensitivity of both of these modalities are not ideal (Holmström 2009). The consequences of heightened anxiety, further examinations through biopsies, and the considerable side effects associated with various prostate cancer treatments must Phillip Kuo, MD, PhD: I will take a moment to comment on the sensitivity of these PSMA [prostate-specific membrane antigen] PET [positron emission tomography] scans compared to conventional imaging.As you said, there have been multiple studies where they basically take patients for whom, by conventional imaging—particularly with regard to biochemical recurrence—they cannot find where the Introduction. Prostate cancer (PC) is one of the most common malignancies and leading causes of cancer death in men worldwide. 1,2 In 2010, PC resulted in 256,000 deaths globally. 1 The American Cancer Society has estimated that 16% of American men will develop PC during their lifetime, with 3.4% at risk of death eventually. 3 Prostate-specific antigen (PSA) is a commonly used test for early Results tPSA sensitivities ranged from 0.78 to 1.00 and specificities from 0.06 to 0.66. Positive likelihood ratios ranged from 0.83 to 2.90 and negative likelihood ratios ranged from 0.00 to 3.75 Conclusion tPSA has a role to play as one of several indicators for prostate biopsy along with abnormal digital rectal examination and urinary symptoms. A total of 1029 men had a urinary PCA3 test prior to having a prostate biopsy for suspicion of prostate cancer. The median PCA3 score was higher in those with positive biopsies. At a cutoff of 35, sensitivity was 68%, specificity 71%, positive and negative predictive values 67% and 71%, and 69% accuracy. 9tsq3.